InsidersTradesSigma
CEL SCI CORP Stock: price and insider trades · United States · SEC (Form 4)
Track the CEL SCI CORP share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, CEL SCI CORP has logged 88 reports. Market capitalisation: €19.9m. The latest transaction was disclosed on 1 July 2026 (Attribution). Among the most active insiders: KERSTEN GEERT R. Every trade is openly available.
88
Insider Decl.
0
Thresholds
€612,357
12 ops.
Buy Volume
€290,149
2 ops.
Sell Volume
42Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations88 total
5,192 sharesCommon StockSEC:0001236030-26-000006:0
4,125 sharesCommon StockSEC:0001236215-26-000003:0
2,307 sharesCommon StockSEC:0001238028-26-000003:0
100,000 shares@ US$1.190.14% mcap21.8% of flowCommon StockSEC:0001236030-26-000004:0
Ideal exit: 7 Feb 2027 (T+270)
10,416 shares@ US$0.23040.7% of flowCommon StockSEC:0001236030-25-000003:0
22,786 shares@ US$0.23040.9% of flowCommon StockSEC:0001236030-25-000001:0
15,432 shares@ US$0.23043.9% of flowCommon StockSEC:0001236030-25-000002:0
10,727 shares@ US$0.405.0% of flowCommon StockSEC:0001236215-25-000001:0
12,940 shares@ US$0.400.9% of flowCommon StockSEC:0001236215-25-000003:0
6,001 shares@ US$0.400.7% of flowCommon StockSEC:0001236215-25-000002:0
4,047 shares@ US$1.064.6% of flowCommon StockSEC:0001236215-24-000002:0
2,264 shares@ US$1.060.6% of flowCommon StockSEC:0001236215-24-000003:0
4,882 shares@ US$1.060.8% of flowCommon StockSEC:0001236215-24-000001:0
4,461 shares@ US$1.160.9% of flowCommon StockSEC:0001236030-24-000016:0
2,068 shares@ US$1.160.7% of flowCommon StockSEC:0001236030-24-000018:0
3,698 shares@ US$1.164.8% of flowCommon StockSEC:0001236030-24-000017:0
20,000 shares@ US$1.3960.5% of flowCommon StockSEC:0001236030-24-000015:0
Ideal exit: 2 Feb 2025 (T+270)
30,000 shares@ US$1.396.9% of flowCommon StockSEC:0001236030-24-000013:0
Ideal exit: 2 Feb 2025 (T+270)
8,000 shares@ US$1.3912.4% of flowCommon StockSEC:0001236030-24-000014:0
Ideal exit: 2 Feb 2025 (T+270)
1,256 shares@ US$1.910.7% of flowCommon StockSEC:0001236030-24-000006:0
2,246 shares@ US$1.914.8% of flowCommon StockSEC:0001236030-24-000005:0
2,709 shares@ US$1.910.9% of flowCommon StockSEC:0001236030-24-000004:0
1,819 shares@ US$2.720.8% of flowCommon StockSEC:0001236030-24-000001:0
1,577 shares@ US$2.724.7% of flowCommon StockSEC:0001236030-24-000002:0
882 shares@ US$2.720.7% of flowCommon StockSEC:0001236030-24-000003:0
25 of 88 declarations
About CEL SCI CORP
CEL-SCI Corp. (ticker: CVM) is a U.S.-listed biotechnology company traded on NYSE American, making it a small-cap healthcare name with high clinical and financing risk. The company was incorporated in 1983 in Colorado and is now headquartered in Vienna, Virginia, United States. Its business model is centered on research and development rather than commercial operations, with an almost singular focus on cancer immunotherapy. CEL-SCI’s lead program is Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy being developed primarily for advanced, previously untreated head and neck cancer. According to the latest SEC filings, Multikine is intended to be administered locally at the tumor site soon after diagnosis and before surgery or radiation, with the goal of stimulating an anti-tumor immune response while the immune system is still intact. The company also describes a manufacturing footprint near Baltimore, Maryland, that has been developed in anticipation of potential commercialization. From a competitive standpoint, CEL-SCI occupies a narrow niche. It does not yet have a diversified commercial portfolio or meaningful recurring product revenue, so the equity story is driven mainly by clinical progress, regulatory milestones, and access to capital. In oncology immunotherapy, competition is intense, with large pharmaceutical companies and numerous biotech peers pursuing alternative mechanisms and combinations. CEL-SCI’s differentiation lies in Multikine’s distinct treatment timing and cytokine-based design, but the execution risk remains substantial. Recent company developments include continued work on the Multikine program, ongoing regulatory and partnering activity outside the United States, and an August 2025 Breakthrough Medicine Designation application submitted to the Saudi Food and Drug Authority for Multikine in Saudi Arabia through Dallah Pharma. Recent SEC disclosures also emphasize that CEL-SCI remains a late clinical-stage company with no approved products and continued dependence on external financing. For investors in French-speaking markets, CVM is therefore best viewed as a highly speculative biotech single-asset story: potentially meaningful upside if the program advances, but also elevated dilution risk and high sensitivity to clinical and regulatory news.
